We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

165 hedge funds and large institutions have $1.98B invested in Viridian Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more funds holding in top 10

Funds holding in top 10: 1 → 10 (+9)

175% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 16

118% more capital invested

Capital invested by funds: $906M → $1.98B (+$1.07B)

61% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 41

20% more funds holding

Funds holding: 138 → 165 (+27)

4.75% more ownership

Funds ownership: 109.13% → 113.88% (+4.8%)

8% more call options, than puts

Call options by funds: $13.9M | Put options by funds: $12.9M

Holders
165
Holders Change
+27
Holders Change %
+19.57%
% of All Funds
2.37%
Holding in Top 10
10
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+900%
% of All Funds
0.14%
New
44
Increased
66
Reduced
41
Closed
16
Calls
$13.9M
Puts
$12.9M
Net Calls
+$1.01M
Net Calls Change
+$3.94M

Top Buyers

1
DCM
Driehaus Capital Management
Illinois
+$32.6M
2
EC
EcoR1 Capital
California
+$32M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.3M
4
FFM
Fairmount Funds Management
Pennsylvania
+$26.2M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$19.7M

Top Sellers

1
MC
Maverick Capital
Texas
-$21.4M
2
PCH
Polar Capital Holdings
United Kingdom
-$11.6M
3
GTC
Ghost Tree Capital
New York
-$8.38M
4
RI
RTW Investments
New York
-$7.88M
5
State Street
State Street
Massachusetts
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
51
Balyasny Asset Management
Illinois
$7.71M +$5.54M +339,089 New
Dimensional Fund Advisors
52
Dimensional Fund Advisors
Texas
$7.44M +$3.59M +219,500 +204%
IHAM
53
Integral Health Asset Management
New York
$5.69M +$4.09M +250,000 New
Citadel Advisors
54
Citadel Advisors
Florida
$5.49M +$3.21M +196,596 +440%
Wellington Management Group
55
Wellington Management Group
Massachusetts
$5.37M -$786K -48,057 -17%
N
56
Nuveen
North Carolina
$5.2M -$4.41M -270,018 -54%
KFO
57
Kopp Family Office
Minnesota
$4.68M – – –
HWAM
58
Hennion & Walsh Asset Management
New Jersey
$4.49M +$303K +18,546 +10%
HS
59
HighVista Strategies
Massachusetts
$4.21M -$217K -13,244 -7%
Bank of America
60
Bank of America
North Carolina
$4.12M -$486K -29,708 -14%
EAM
61
Exome Asset Management
New York
$3.97M +$2.85M +174,400 New
Principal Financial Group
62
Principal Financial Group
Iowa
$3.93M +$2.66M +162,665 +1,603%
Bank of New York Mellon
63
Bank of New York Mellon
New York
$3.89M -$619K -37,846 -18%
PAM
64
Panagora Asset Management
Massachusetts
$3.83M +$2.75M +168,433 New
ACM
65
Atika Capital Management
New York
$3.8M +$2.73M +167,000 New
PAMP
66
Polar Asset Management Partners
Ontario, Canada
$3.71M +$868K +53,100 +48%
CM
67
Crestline Management
Texas
$3.47M +$2.49M +152,542 New
BFM
68
Boothbay Fund Management
New York
$3.34M +$2.4M +146,749 New
Macquarie Group
69
Macquarie Group
Australia
$3.26M +$1.86M +114,025 +388%
TI
70
Trexquant Investment
Connecticut
$3.25M +$1.65M +100,817 +241%
JF
71
Jump Financial
Illinois
$3.23M +$2.01M +123,178 +655%
D.E. Shaw & Co
72
D.E. Shaw & Co
New York
$3.14M +$2.26M +138,067 New
Barclays
73
Barclays
United Kingdom
$2.85M +$1.09M +66,550 +113%
AG
74
Algert Global
California
$2.61M +$971K +59,420 +107%
Swiss National Bank
75
Swiss National Bank
Switzerland
$2.46M +$253K +15,500 +17%
1 2
3
4 5

VRDN Hedge Fund Activity: Q3 2024 in Review

165 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2024, worth a combined $1.98B — up 118% from $906M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new VRDN positions and 16 closed out — a net gain of 28 holders — while 66 added to existing stakes and 41 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $32.6M. The largest seller was Maverick Capital, cutting an estimated $21.4M.

  • 165 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2024, up from 138 in Q2 2024.
  • Funds reported $1.98B of Viridian Therapeutics stock for Q3 2024, up 118% quarter-over-quarter.
  • 44 funds opened new Viridian Therapeutics positions in Q3 2024 and 16 closed out, a net change of +28 holders.
  • The largest Viridian Therapeutics buyer in Q3 2024 was Driehaus Capital Management, an estimated $32.6M added.
  • The largest Viridian Therapeutics seller in Q3 2024 was Maverick Capital, an estimated $21.4M sold.

Based on aggregated 13F filings for Q3 2024.